These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 18798018

  • 1. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy.
    Jessen C, Agerbaek M, Von Der Maase H.
    Acta Oncol; 2009; 48(3):411-7. PubMed ID: 18798018
    [Abstract] [Full Text] [Related]

  • 2. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer.
    Als AB, Dyrskjøt L, von der Maase H, Koed K, Mansilla F, Toldbod HE, Jensen JL, Ulhøi BP, Sengeløv L, Jensen KM, Orntoft TF.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4407-14. PubMed ID: 17671123
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Advanced seminoma--treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients.
    Gholam D, Fizazi K, Terrier-Lacombe MJ, Jan P, Culine S, Theodore C.
    Cancer; 2003 Aug 15; 98(4):745-52. PubMed ID: 12910518
    [Abstract] [Full Text] [Related]

  • 11. Angiotensin-II combined intra-arterial chemotherapy for locally advanced bladder cancer: a case series study at a single institution.
    Shimabukuro T, Nakamura K, Uchiyama K, Tei Y, Aoki A, Naito K.
    Hinyokika Kiyo; 2006 Feb 15; 52(2):99-105. PubMed ID: 16541762
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer.
    Sengeløv L, Kamby C, Geertsen P, Andersen LJ, von der Maase H.
    Cancer Chemother Pharmacol; 2000 Feb 15; 46(5):357-64. PubMed ID: 11127939
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy.
    Kastritis E, Dimopoulos MA, Antoniou N, Deliveliotis C, Chrisofos M, Skolarikos A, Gika D, Bamias A.
    Anticancer Res; 2006 Feb 15; 26(5B):3865-9. PubMed ID: 17094415
    [Abstract] [Full Text] [Related]

  • 17. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer.
    Abe T, Shinohara N, Harabayashi T, Sazawa A, Maruyama S, Suzuki S, Nonomura K.
    Eur Urol; 2007 Oct 15; 52(4):1106-13. PubMed ID: 17367917
    [Abstract] [Full Text] [Related]

  • 18. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only.
    de Vries RR, Nieuwenhuijzen JA, Meinhardt W, Bais EM, Horenblas S.
    Eur J Surg Oncol; 2009 Apr 15; 35(4):352-5. PubMed ID: 18722076
    [Abstract] [Full Text] [Related]

  • 19. Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study.
    Schmidt H, Geertsen PF, Fode K, Rytter C, Bastholt L, von der Maase H.
    Melanoma Res; 2000 Feb 15; 10(1):66-77. PubMed ID: 10711642
    [Abstract] [Full Text] [Related]

  • 20. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
    Kiyota N, Tahara M, Kadowaki S, Fuse N, Doi T, Minami H, Ohtsu A.
    Jpn J Clin Oncol; 2009 Apr 15; 39(4):225-30. PubMed ID: 19211574
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.